2-(氰基甲基)苯甲酰胺 | 358632-71-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(氰基甲基)苯甲酰胺
• 中文别名: 咪唑并[1,5,4-ef] [1,5]苯并二氮杂(8CI，9CI)
• 英文名称: 2-(Cyanomethyl)benzamide
• CAS: 358632-71-0
• 化学式: C₉H₈N₂O
• mdl: MFCD01646245
• 分子量: 160.17
• InChiKey: KOHOTMOOESKQGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] INHIBITORS OF CD40-CD154 BINDING<br/>[FR] INHIBITEURS DE LIAISON CD40-CD154
  申请人：TONIX PHARMACEUTICALS HOLDING CORP

  公开号：WO2020210831A1

  公开（公告）日：2020-10-15

  Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L. The compounds are useful for treating, ameliorating or preventing an autoimmune disease, inflammatory disease, or other immune-related disease in a patient in need of treatment.

  本文披露了包括药用可接受的盐、酯、前药、水合物和互变异构体在内的化合物，这些化合物调节CD-40-CD40L的相互作用。这些化合物可用于治疗、改善或预防患有自身免疫疾病、炎症性疾病或其他免疫相关疾病的患者。
• [EN] 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE<br/>[FR] COMPOSÉS HÉTÉROARYLES À 5 CHAÎNONS CONTENANT UNE FRACTION HYDROXAMATE ET LEUR UTILISATION
  申请人：UNIV LILLE

  公开号：WO2020148403A1

  公开（公告）日：2020-07-23

  The present invention is directed to 5-membered heteroaryl compounds containing a hydroxamate moiety of Formula I, pharmaceutically acceptable salts or solvates thereof, and their use as sensitizers for chemotherapy of malignant tumors.

  本发明涉及含有Formula I的羟肟基团的5-成员杂芳化合物，其药用可接受盐或溶剂，以及它们作为恶性肿瘤化疗的增敏剂的用途。
• [EN] INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS<br/>[FR] INHIBITION DE PROTÉINES SH2 INDUITES PAR DES CYTOKINES DANS DES CELLULES NK
  申请人：THE WALTER AND ELIZA HALL INST OF MEDICAL RES

  公开号：WO2017100861A1

  公开（公告）日：2017-06-22

  The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.

  本发明涉及基于抑制NK细胞中CIS的治疗和预防方法。具体而言，本发明涉及通过向受试者施用CIS抑制剂或施用CIS抑制的NK细胞来治疗或预防NK细胞响应性疾病。本发明还涉及识别CIS抑制剂的方法，以及确定癌症对CIS抑制治疗的反应可能性的方法。
• PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：YM Biosciences Australia Pty Ltd

  公开号：US20140011803A1

  公开（公告）日：2014-01-09

  The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

  本发明涉及苯基氨基嘧啶化合物，它们是蛋白激酶（包括JAK激酶）的抑制剂。特别地，这些化合物对JAK2激酶具有选择性。这些激酶抑制剂可用于治疗与激酶相关的疾病，如免疫和炎症性疾病，包括器官移植；过度增殖性疾病，包括癌症和骨髓增生性疾病；病毒性疾病；代谢性疾病；以及血管性疾病。
• Preparation of bromoacetamides
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0144177A1

  公开（公告）日：1985-06-12

  Bromoacetamides of the formula ArCONHCH(Br)CONH2 are obtained by addition to bromine of a solution of ArCONHCH2CN in a saturated aliphatic carboxylic acid preferably glacial acetic or propionic acid. This is an improvement in a process described in European Patent Specification No. 0059536 in which the bromine is added to a solution of the cyanomethylbenzamide, enabling consistently high yields (e.g. 75 to 90%) to be obtained.

  通过将 ArCONHCH2CN 在饱和脂肪族羧酸（最好是冰醋酸或丙酸）中的溶液加入溴，可获得式为 ArCONHCH(Br)CONH2 的溴乙酰胺。这是对欧洲专利说明书第 0059536 号中描述的工艺的改进，在该工艺中，溴被添加到氰甲基苯甲酰胺的溶液中，从而能够获得稳定的高产率（例如 75% 至 90%）。